Skip to main content
. 2013 Aug 30;8(8):e72789. doi: 10.1371/journal.pone.0072789

Table 1. Patient cohorts and characteristics.

Age Males:Females CD4+ T cell count cells/mm3 Viral load(HIV RNA copies/mL plasma) %CD3+CD4+ %CD3+CD8+ %CD4+HLA-DR+ %CD8+HLA-DR+ Years diagnosed Years on HAART HAARTregimen
HIV-negative(HIV-) n = 40 38(21–63) 17∶20 N/A N/A 67.3%(46.7–91.9) 23.2%(4.4–46.0) 4.90%(1.44–22.0) 6.96%(0.55–28.50) N/A N/A N/A
HIV-infected,therapy-naïve n = 34 41(20–77) 28∶6 506(18–1353) 76,390(<50–976,464) 41.8%****(10.5–70.7) 44.0%****(17.2–66.4) 12.27%****(1.720–44.20) 20.20%****(1.24–58.70) 6.06(1–23) N/A N/A
HIV-infected,HAART n = 63 50(30–64) 47∶13 497(96–1578) <50 47.9%****(16.9–90.4) 40.0%****(3.4–74.4) 9.21%**(1.22–27.40) 9.69%(0.12–32.20) 6.06(1–23) 6.96(2–20) PI, NNRTI, combination

Age, T cell counts, viral loads, years diagnosed and years on HAART are expressed as mean values with the range indicated in parentheses. CD4+ T cell counts and plasma viral load are not applicable (N/A) for HIV-negative controls. Plasma viral load was under 50 HIV RNA copies/mL plasma in HIV-infected, HAART-treated group. (PI = protease inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, combination = PI+NNRTI). P values determined using ANOVA followed by Bonferroni’s Multiple Comparisons test (**P<0.01, ****P<0.001 compared to HIV-negative controls.

P<0.001 compared to HIV, therapy naïve.).